Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36 N.6, and our video podcast, CANCER BUZZ TV.
 

Share

    


Home / Eliminating Disparities / Precision Medicine Disparities Detail

[Abstract 123] Identifying barriers to equitable biomarker testing in underserved patients with NSCLC: A mixed-methods study to inform quality improvement opportunities

September 24, 2021

Authors

Leigh Boehmer, Upal Kunal Basu Roy, Janelle Schrag, Nikki A. Martin, Gregory D. Salinas, Brandon Coleman, Alexandra Howson, Latha Shivakumar

Association of Community Cancer Centers, Rockville, MD, LUNGevity Foundation, Bethesda, MD, CE Outcomes, Birmingham, AL, CE Outcomes, LLC, Birmingham, AL, Thistle Editorial, LLC, Snoqualmie, WA

Background

Despite recent advances in cancer precision medicine, patients from underserved communities do not have equal access to biomarker testing and targeted therapies. This study used a mixed-methods approach to identify barriers to equitable precision medicine access among underserved patients with non-small cell lung cancer (NSCLC).

Methods

Paired national surveys (one clinician-facing and one patient-facing) were developed respectively by the Association of Community Cancer Centers (ACCC) and LUNGevity Foundation. Administered online in spring/summer 2020, the surveys were designed to identify key attitudes/barriers related to biomarker testing, resource needs, and current practice patterns for pertinent stakeholders. Survey data was triangulated with data from focus groups (2 clinician and 6 patient) conducted in fall 2020. The study was approved by Advarra IRB.

Results

A total of 99 clinicians responded, with 67% (66/99) representing oncologists from community cancer programs. 248 patients responded to the LUNGevity survey, with 161 coming from the general population and 87 from the LUNGevity network (patients with relatively high income and education levels). Most clinicians surveyed indicated they were “very” (34%) or “extremely” likely (44%) to discuss biomarker testing with NSCLC patients. Academic clinicians, however, were more likely than community-based clinicians to order testing at the time of initial biopsy (76% vs 52%, P =.02). Academic clinicians were also more likely to involve the patient’s family in biomarker testing discussions (85% vs 59%, P =.009). Patient survey results identified that medical oncologists are the primary source of biomarker testing information; 64% of LUNGevity-connected and 37% of underserved patients. Eighty-five percent of LUNGevity-connected patients receive biomarker testing versus 52% for general patients (p < 0.05). Notably, more than a quarter (27%) of underserved patients who have undergone biomarker testing do not know their results. Clinician focus group participants corroborated survey findings that most clinicians receive testing results in 7-14 days, but for 23% of community and 6% of academic clinicians the process can take over 2 weeks. They identified disparities in offering biomarker testing and results to patients with known or presumed low socioeconomic status (SES) and/or health literacy. This was supported by patient survey data, which showed biomarker testing was proactively offered to only 40% of low-SES patients.

Conclusions

This study identifies key areas of ongoing need related to equitable biomarker testing. Quality-improvement opportunities exist to address both clinician and patient barriers to guideline-concordant biomarker testing for underserved patients with NSCLC.

Acknowledgements and Disclosures:

The authors would like to thank the ACCC committee members, as well as the clinician and patient survey panelists. This study was supported by Genentech, Foundation Medicine, Janssen, Merck, Amgen

Our Partner


Our Supporters

FoundationMedicine-200x80

Funding & support provided by Genentech, Janssen, Merck & Co., and Foundation Medicine